iNstroke 抽吸导管用于血栓切除术的评估:一项多中心前瞻性研究。 (iNDUO)
前瞻性、单臂、多中心研究,旨在确认 iNstroke 6F 和 4F 血栓抽吸导管治疗急性缺血性卒中的性能与安全性
Prospective, single-arm, multi-center study to confirm the performance and safety of the iNstroke 6F and 4F thromboaspiration catheter for the treatment of acute ischemic stroke
研究概览
详细说明
This clinical investigation has been designed to generate further data demonstrating the safety and effectiveness of the iNstroke device as well as of the thrombectomy process for the treatment of large and medium vessel occlusions.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Bremen、德国
- Klinikum Bremen Mitte
-
接触:
- Panagiotis Papanagiotou
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Panagiotis Papanagiotou, Dr.
-
Cologne、德国
- Universität zu Köln
-
接触:
- Christoph Kabbasch
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Christoph Kabbasch, Dr.
-
Dortmund、德国
- Knappschaft Kliniken
-
接触:
- Jens Altenbernd
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Jens Altenbernd, Dr.
-
Hamburg、德国
- UKE Hamburg
-
接触:
- Fabian Flottmann
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Fabian Flottmann, Dr.
-
Nuremberg、德国
- Klinikum Nürnberg
-
接触:
- Markus Holtmannspötter
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Markus Holtmannspötter, Prof. Dr.
-
-
-
-
-
Bordeaux、法国
- CHU Bordeaux (H Pellegrin)
-
接触:
- Xavier Barreau
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Xavier Barreau, Dr.
-
Brest、法国
- CHU Brest
-
接触:
- Jean Christoph Gentric
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Jean Christoph Gentric, Dr.
-
Lille、法国
- CHU Lille
-
接触:
- Nicolas Bricout
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Nicolas Bricout, Dr.
-
Nancy、法国
- CHU Nancy
-
接触:
- Benjamin Gory
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Benjamin Gory, Dr.
-
Paris、法国
- APHP Pitié Salpétrière
-
接触:
- Clarencon Frédéric
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
首席研究员:
- Frédéric Clarencon, Dr.
-
Strasbourg、法国
- CHU Strasbourg
-
首席研究员:
- Frédéric Clarencon, Dr.
-
接触:
- Raoul Pop
- 电话号码:+34 936724711
- 邮箱:clinica@ivascular.global
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients ≥ 18 years of age.
- Able to be treated (i.e., defined by arterial puncture time) within 24 hours of symptom onset or last time seen well (LTSW).
- Demonstrated occlusion in a large and/or medium vessel (carotid T, M1, proximal M2, M2-M3, A1, A2, A3, basilar artery, P1, P2, P3).
- Baseline NIHSS score ≥6 assessed before the procedure.
- Pre-morbid [xB13.1]stroke baseline mRS ≤ 2.
- Subjects with an ASPECTS ≥ 6.
- Informed consent signed by the subject or their representative, or notice of information, as per regulatory requirements, to collect the subject's data.
- As applicable by French laws, the subject is affiliated to a health social security regimen or equivalent (only to be answered by French sites).
Exclusion Criteria:
- Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
- Severe allergy to contrast media.
- As applicable by French laws: breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, or persons of full age who are the subject of a legal protection measure.
- Patients with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
- Multiple Intracranial Occlusions
- Known medical history of thrombocytopenia (Platelets <100,000).
- Presence of intracerebral hemorrhage.
- Significant mass effect and/or midline shift.
- Evidence of intracranial tumor (except small meningioma).
- Intracranial stenosis proximal to the occlusion.
- Severe sustained hypertension (systolic pressure >185 mm Hg or diastolic pressure >110 mm Hg). Note: If blood pressure can be successfully reduced and maintained at an acceptable level by administering the medication recommended by the ESO (European Stroke Organisation) in its guidelines (also IV infusion of antihypertensives), the patient may be included.
- Known or suspected cerebral vasculitis.
- Known renal insufficiency with creatinine ≥3 mg/dl or Glomerular Filtration Rate (GFR) <30 mL/min.
- Current participation in an interventional drug or device study that may confound the results of this study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Thromboaspiration using iNstroke 4F and/or iNstroke 6F aspiration catheter
No comparator will be used in this clinical investigation as it is an exploratory study of a CE-marked medical device to be used within the scope of its intended purpose. |
Patients to undergo thromboaspiration with iNstroke 6F and/or 4F |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recanalization Rate
大体时间:Intra-procedure
|
Recanalization rate with mTICI ≥2b in ≤3 revascularization passes using iNstroke Thrombus Extraction Aspiration Device aspiration catheter alone, or in conjunction with Stent Retriever. |
Intra-procedure
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.